Observational Study About Patients Diagnosed With NAFLD

Launched by XIANGYA HOSPITAL OF CENTRAL SOUTH UNIVERSITY · Nov 15, 2022

Keywords

ClinConnect Summary

This clinical trial is studying nonalcoholic fatty liver disease (NAFLD), a common liver condition linked to obesity and metabolic issues. NAFLD can start with fat buildup in the liver, which may lead to more serious problems like inflammation and liver damage over time. The goal of the study is to better understand this disease and help develop safe and effective treatments for those affected.

To participate in the trial, individuals need to have a diagnosis of NAFLD. However, those with certain health conditions, such as excessive alcohol use, cancer, or active infections, cannot join. Participants will be recruited from a wide age range and both men and women can take part. If eligible, participants will be asked to sign a consent form and may undergo tests to gather important information about their liver health. This study aims to build a clearer picture of NAFLD so that better treatment options can be created in the future.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • 1. patients diagnosed with nonalcoholic fatty liver disease
• Exclusion Criteria:
• • 1. patients suspected of excessive alcohol consumption
• • 2. malignant tumors, dementia, active tuberculosis, AIDS, organ failure, pregnancy or breastfeeding, etc cannot cooperate with the investigation
• • 3. incomplete data such as HBV serological results and abdominal ultrasound results
• • 4. patients who refuse to sign informed consent